Symbols / MAIA $1.29 -1.53% MAIA Biotechnology, Inc.
MAIA Chart
Stock Fundamentals
|
|
|
|
|
|
About
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Ratings
Current target
$1.29
Low
$10.27
High
$14.00
Mean
$12.14
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-02-21 | init | Noble Capital Markets | — → Outperform | $14 |
- MAIA Biotechnology (MAIA) boosts cash with $33M raise as NSCLC trials advance - Stock Titan Mon, 11 May 2026 13
- MAIA Biotechnology, Inc. 1Q 2026: Net income $(6.37M), EPS $(0.14) — 10-Q Summary - TradingView Mon, 11 May 2026 13
- MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock - Yahoo Finance Mon, 02 Mar 2026 08
- $2.3M NIH-backed lung cancer study opens first U.S. site - Stock Titan hu, 16 Apr 2026 07
- $MAIA stock is down 29% today. Here's what we see in our data. | MAIA Stock News - Quiver Quantitative ue, 03 Mar 2026 08
- MAIA Biotechnology opens first U.S. site for lung cancer trial - Investing.com hu, 16 Apr 2026 07
- $MAIA stock is down 17% today. Here's what we see in our data. - Quiver Quantitative hu, 29 Jan 2026 08
- Cancer immunotherapy firm MAIA raises $30M for trials, costs - Stock Titan Mon, 02 Mar 2026 08
- MAIA Biotechnology Activates First U.S. Site for THIO-101 Phase 2 Trial, Reporting Promising Efficacy in Advanced NSCLC Treatment - Quiver Quantitative hu, 16 Apr 2026 07
- MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Yahoo Finance Mon, 02 Mar 2026 08
- Cancer immunotherapy developer MAIA plans stock sale to fund trials - Stock Titan Mon, 02 Mar 2026 08
- Cancer drug developer MAIA raises $30M to fund new trials - Stock Titan Wed, 04 Mar 2026 08
- MAIA Biotechnology (MAIA) CEO awarded 800,000 stock options at $1.28 - Stock Titan ue, 14 Apr 2026 07
- MAIA Biotechnology (MAIA) grants 30,000 stock options to finance head - Stock Titan ue, 14 Apr 2026 07
- $33M gives MAIA runway to finish late-stage lung cancer study - Stock Titan Wed, 08 Apr 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
23.91
+41.66%
|
16.88
-15.64%
|
20.01
+26.12%
|
15.86
|
| Research And Development |
|
14.55
+45.34%
|
10.01
-9.93%
|
11.11
+24.39%
|
8.93
|
| Selling General And Administration |
|
9.72
+39.93%
|
6.95
-23.40%
|
9.07
+47.64%
|
6.14
|
| General And Administrative Expense |
|
9.72
+39.93%
|
6.95
-23.40%
|
9.07
+47.64%
|
6.14
|
| Other Gand A |
|
9.72
+39.93%
|
6.95
-23.40%
|
9.07
+47.64%
|
6.14
|
| Other Operating Expenses |
|
-0.36
-351.95%
|
-0.08
+54.76%
|
-0.18
-122.49%
|
0.79
|
| Total Expenses |
|
23.91
+41.66%
|
16.88
-15.64%
|
20.01
+26.12%
|
15.86
|
| Operating Income |
|
-23.91
-41.66%
|
-16.88
+15.64%
|
-20.01
-26.12%
|
-15.86
|
| Total Operating Income As Reported |
|
-24.27
-43.12%
|
-16.96
+15.98%
|
-20.18
-24.77%
|
-16.18
|
| EBITDA |
|
-22.40
+3.69%
|
-23.25
-17.65%
|
-19.77
-25.40%
|
-15.76
|
| Normalized EBITDA |
|
-23.59
-42.49%
|
-16.56
+17.09%
|
-19.97
-25.92%
|
-15.86
|
| EBIT |
|
-22.40
+3.69%
|
-23.25
-17.65%
|
-19.77
-25.40%
|
-15.76
|
| Total Unusual Items |
|
1.20
+117.90%
|
-6.70
-3364.13%
|
0.21
+108.48%
|
0.10
|
| Total Unusual Items Excluding Goodwill |
|
1.20
+117.90%
|
-6.70
-3364.13%
|
0.21
+108.48%
|
0.10
|
| Special Income Charges |
|
—
|
—
|
—
|
0.00
|
| Other Special Charges |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-22.40
+3.69%
|
-23.25
-17.61%
|
-19.77
-25.39%
|
-15.77
|
| Pretax Income |
|
-22.40
+3.69%
|
-23.25
-17.61%
|
-19.77
-25.39%
|
-15.77
|
| Net Non Operating Interest Income Expense |
|
0.31
-1.37%
|
0.32
+1052.17%
|
0.03
+642.02%
|
-0.01
|
| Interest Expense Non Operating |
|
0.00
-100.00%
|
0.00
-99.17%
|
0.01
-1.49%
|
0.01
|
| Net Interest Income |
|
0.31
-1.37%
|
0.32
+1052.17%
|
0.03
+642.02%
|
-0.01
|
| Interest Expense |
|
0.00
-100.00%
|
0.00
-99.17%
|
0.01
-1.49%
|
0.01
|
| Interest Income Non Operating |
|
0.31
-1.39%
|
0.32
+823.07%
|
0.03
+1744.39%
|
0.00
|
| Interest Income |
|
0.31
-1.39%
|
0.32
+823.07%
|
0.03
+1744.39%
|
0.00
|
| Other Income Expense |
|
1.20
+117.90%
|
-6.70
-3364.13%
|
0.21
+108.48%
|
0.10
|
| Gain On Sale Of Security |
|
1.20
+117.90%
|
-6.70
-3364.13%
|
0.21
+108.48%
|
0.10
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-22.40
+3.69%
|
-23.25
-17.61%
|
-19.77
-25.39%
|
-15.77
|
| Net Income From Continuing Operation Net Minority Interest |
|
-22.40
+3.69%
|
-23.25
-17.61%
|
-19.77
-25.39%
|
-15.77
|
| Net Income From Continuing And Discontinued Operation |
|
-22.40
+3.69%
|
-23.25
-17.61%
|
-19.77
-25.39%
|
-15.77
|
| Net Income Continuous Operations |
|
-22.40
+3.69%
|
-23.25
-17.61%
|
-19.77
-25.39%
|
-15.77
|
| Minority Interests |
|
—
|
—
|
—
|
0.00
|
| Normalized Income |
|
-23.59
-42.49%
|
-16.56
+17.11%
|
-19.98
-25.90%
|
-15.87
|
| Net Income Common Stockholders |
|
-22.40
+3.69%
|
-23.25
-17.61%
|
-19.77
-21.91%
|
-16.22
|
| Otherunder Preferred Stock Dividend |
|
—
|
—
|
0.00
-100.00%
|
0.45
|
| Diluted EPS |
|
—
|
-1.05
+29.53%
|
-1.49
+14.86%
|
-1.75
|
| Basic EPS |
|
—
|
-1.05
+29.53%
|
-1.49
+14.86%
|
-1.75
|
| Basic Average Shares |
|
—
|
22.20
+67.38%
|
13.26
+42.95%
|
9.28
|
| Diluted Average Shares |
|
—
|
22.20
+67.38%
|
13.26
+42.95%
|
9.28
|
| Diluted NI Availto Com Stockholders |
|
-22.40
+3.69%
|
-23.25
-17.61%
|
-19.77
-21.91%
|
-16.22
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
7.57
|
| Current Assets |
|
7.56
|
| Cash Cash Equivalents And Short Term Investments |
|
7.15
|
| Cash And Cash Equivalents |
|
7.15
|
| Cash Financial |
|
7.15
|
| Receivables |
|
0.14
|
| Other Receivables |
|
0.14
|
| Prepaid Assets |
|
—
|
| Other Current Assets |
|
0.27
|
| Total Non Current Assets |
|
0.00
|
| Non Current Deferred Assets |
|
0.00
|
| Other Non Current Assets |
|
0.00
|
| Total Liabilities Net Minority Interest |
|
7.09
|
| Current Liabilities |
|
4.94
|
| Payables And Accrued Expenses |
|
3.33
|
| Payables |
|
1.64
|
| Accounts Payable |
|
1.64
|
| Current Accrued Expenses |
|
1.69
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
1.61
|
| Current Deferred Liabilities |
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
2.15
|
| Stockholders Equity |
|
0.48
|
| Common Stock Equity |
|
0.48
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
16.99
|
| Ordinary Shares Number |
|
16.99
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
64.47
|
| Retained Earnings |
|
-63.98
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.02
|
| Minority Interest |
|
—
|
| Other Equity Adjustments |
|
-0.02
|
| Total Equity Gross Minority Interest |
|
0.48
|
| Total Capitalization |
|
0.48
|
| Working Capital |
|
2.63
|
| Invested Capital |
|
0.48
|
| Net Tangible Assets |
|
0.48
|
| Tangible Book Value |
|
0.48
|
| Derivative Product Liabilities |
|
2.15
|
| Dueto Related Parties Current |
|
—
|
| Interest Payable |
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-18.84
-20.00%
|
-15.70
-20.15%
|
-13.07
-8.06%
|
-12.10
|
| Cash Flow From Continuing Operating Activities |
|
-18.84
-20.00%
|
-15.70
-20.15%
|
-13.07
-8.06%
|
-12.10
|
| Net Income From Continuing Operations |
|
-22.40
+3.69%
|
-23.25
-17.61%
|
-19.77
-25.39%
|
-15.77
|
| Other Non Cash Items |
|
0.62
+244.76%
|
0.18
-75.47%
|
0.73
-33.45%
|
1.10
|
| Stock Based Compensation |
|
2.63
+37.59%
|
1.91
-38.08%
|
3.09
+33.19%
|
2.32
|
| Operating Gains Losses |
|
-1.20
-117.90%
|
6.70
+3364.13%
|
-0.21
-108.48%
|
-0.10
|
| Gain Loss On Investment Securities |
|
-1.20
-117.90%
|
6.70
+3364.13%
|
-0.21
-108.48%
|
-0.10
|
| Change In Working Capital |
|
1.50
+221.13%
|
-1.24
-140.11%
|
3.09
+774.78%
|
0.35
|
| Change In Receivables |
|
0.08
+41.55%
|
0.06
-64.14%
|
0.16
+158.80%
|
-0.27
|
| Change In Prepaid Assets |
|
-0.58
-195.90%
|
-0.20
-168.55%
|
0.29
+156.57%
|
-0.51
|
| Change In Payables And Accrued Expense |
|
2.00
+281.93%
|
-1.10
-141.59%
|
2.64
+134.39%
|
1.13
|
| Change In Accrued Expense |
|
1.48
+250.95%
|
-0.98
-145.15%
|
2.17
+136.96%
|
0.92
|
| Change In Payable |
|
0.52
+537.38%
|
-0.12
-125.18%
|
0.47
+123.28%
|
0.21
|
| Change In Account Payable |
|
0.52
+537.38%
|
-0.12
-125.18%
|
0.47
+123.28%
|
0.21
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
0.44
|
| Change In Other Current Assets |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Financing Cash Flow |
|
17.91
-1.49%
|
18.18
+96.06%
|
9.27
-25.70%
|
12.48
|
| Cash Flow From Continuing Financing Activities |
|
17.91
-1.49%
|
18.18
+96.06%
|
9.27
-25.70%
|
12.48
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
0.00
|
| Issuance Of Debt |
|
—
|
—
|
—
|
0.00
|
| Repayment Of Debt |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Net Common Stock Issuance |
|
17.62
-6.04%
|
18.75
+64.27%
|
11.42
-18.30%
|
13.97
|
| Proceeds From Stock Option Exercised |
|
0.90
+315.56%
|
0.22
+15064.66%
|
0.00
-99.69%
|
0.47
|
| Net Other Financing Charges |
|
-0.62
+22.40%
|
-0.80
+62.97%
|
-2.15
-9.24%
|
-1.97
|
| Changes In Cash |
|
-0.94
-137.94%
|
2.47
+165.05%
|
-3.80
-1097.24%
|
0.38
|
| Effect Of Exchange Rate Changes |
|
-0.01
+75.79%
|
-0.02
-18314.53%
|
-0.00
+97.36%
|
-0.00
|
| Beginning Cash Position |
|
9.60
+34.27%
|
7.15
-34.70%
|
10.95
+3.56%
|
10.57
|
| End Cash Position |
|
8.66
-9.82%
|
9.60
+34.27%
|
7.15
-34.70%
|
10.95
|
| Free Cash Flow |
|
-18.84
-20.00%
|
-15.70
-20.15%
|
-13.07
-8.06%
|
-12.10
|
| Common Stock Issuance |
|
17.62
-6.04%
|
18.75
+64.27%
|
11.42
-18.30%
|
13.97
|
| Issuance Of Capital Stock |
|
17.62
-6.04%
|
18.75
+64.27%
|
11.42
-18.30%
|
13.97
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-Q2026-05-11 View
- 8-K2026-04-16 View
- 42026-04-14 View
- 42026-04-14 View
- 42026-04-14 View
- 8-K2026-04-08 View
- 42026-04-02 View
- 42026-04-02 View
- 42026-04-02 View
- 42026-04-02 View
- 42026-04-02 View
- 42026-04-02 View
- 8-K2026-04-02 View
- 8-K2026-03-31 View
- 8-K2026-03-27 View
- 10-K2026-03-23 View
- 8-K2026-03-04 View
- 8-K2026-02-24 View
- 8-K2026-01-20 View
- 8-K2026-01-13 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|